Frontiers in immunology
January 1, 2025
David Qixiang Chen, José Adalberto Inzunza Domínguez, Juan Manuel Valle Uzeta et al.
3 citations
Ibogaine treatment in two multiple sclerosis patients led to substantial lesion shrinkage and decreased Apparent Diffusion Coefficient values, suggesting remyelination and reduced inflammation. Both patients showed cortical and subcortical alterations, especially in regions linked to pain and emotional processing. These findings indicate ibogaine may promote neuroplasticity and modulate neurocircuitry involved in MS pathology.
Frontiers in immunology
January 1, 2026
Qing Feng, Zhen Yuan, Qi An et al.
1 citation
Depression involves immune dysregulation, and serum inflammatory cytokines such as IL-1β, IL-6, TNF-α, IFN-γ, and C-reactive protein link peripheral inflammation to brain dysfunction. These cytokines activate innate immune pathways like TLR4, NF-κB, MAPK, and NLRP3 inflammasome, alter tryptophan-kynurenine metabolism via IDO1 and TDO2, impair monoamine neurotransmission, enhance glutamatergic excitotoxicity, reduce BDNF-dependent neuroplasticity, and promote microglia-mediated neuroinflammation. Clinical studies associate cytokine profiles with symptom severity, cognitive dysfunction, suicidality, and illness chronicity. Anti-inflammatory compounds, antidepressants with immunomodulatory effects, and ketamine may work partly by normalizing these cytokine pathways.